The primary study hypotheses are that, without increasing doses of breakthrough medications or device intolerance, the Nometexâ„¢ device worn for 5-days beginning with the day of chemotherapy administration in women with ovarian or advanced endometrial or cervical cancer will, as an adjunct to standard-of-care anti-emetics, reduce vomiting episodes, and reduce the severity of nausea.
The secondary hypotheses are that the Nometexâ„¢ device reduces acute (Day 1) emetic episodes, day 1 and days 2-5 severity of nausea, and delayed (days 2-5) emetic episodes without increasing doses of breakthrough medications or device intolerance.
Women with ovarian (including fallopian tube) or advanced endometrial or cervical cancer Chemotherapy-naïve or who have had previous chemotherapy exposure, but who have not yet received the first infusion 18 years of age or older, and can provide cognizant informed consent presenting to the Helen F. Graham Cancer Center ECOG Status of 0-2 Standardized Antiemetic Regimen
Exclusion Criteria:
Pre-existing or at-risk for a peripheral neuropathy in region of device placement Implanted cardiac pace maker Nickel or other metal allergies Previous experience with median nerve/P6 stimulation Receiving concurrent radiation therapy Previous participants of this study will be excluded from future participation in this study.
